文献速递外周动脉疾病慢性静脉疾病

组学进展与突破性基因治疗:外周动脉疾病未来的展望

Advancements in Omics and Breakthrough Gene Therapies: A Glimpse into the Future of Peripheral Artery Disease.
PubMed 文献 · Ann Vasc Surg · 2024-04-04

本文综述了多组学技术结合人工智能分析在动脉粥样硬化和内膜增生研究中的应用,介绍了病毒与非病毒基因治疗平台、基因编辑技术及生物材料递送系统,重点探讨了针对内膜增生所致静脉移植物中期失败的基因治疗策略及外周动脉疾病相关疾病的靶向基因治疗前景。

要点

  • 多组学与人工智能分析可在单细胞和空间精度上研究动脉粥样硬化与内膜增生。
  • 基因编辑与病毒/非病毒递送平台为外周动脉疾病靶向基因治疗提供可能。
  • 基因治疗尤其适合离体基因工程改造抗内膜增生的静脉移植物。

核心结论

  • 靶向基因治疗的潜在临床转化有望革新外周动脉疾病治疗,从而改善患者生活质量和预期寿命。

研究设计与样本

  • 本文为综述,汇总了当前最先进的多组学方法、有前景的基因治疗候选方案以及本实验室和其他实验室用于阻止内膜增生所致静脉移植物中期失败的基因治疗递送方式。

主要发现

  • 多组学技术结合人工智能驱动的分析工具,已使动脉粥样硬化和内膜增生的研究达到前所未有的单细胞和空间精度。
  • 多项研究已识别出调控关键致动脉粥样硬化和抗动脉粥样硬化信号通路的基因枢纽作为潜在治疗候选。
  • 病毒与非病毒基因治疗平台、基因编辑技术及前沿生物材料储库的进步,使开发安全、高效、靶向外周动脉疾病相关疾病的基因治疗成为可能。
  • 基因治疗似乎尤其适合离体基因工程改造抗内膜增生的静脉移植物。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Peripheral artery disease (PAD), a highly prevalent global disease, associates with significant morbidity and mortality in affected patients. Despite progress in endovascular and open revascularization techniques for advanced PAD, these interventions grapple with elevated rates of arterial restenosis and vein graft failure attributed to intimal hyperplasia (IH). Novel multiomics technologies, coupled with sophisticated analyses tools recently powered by advances in artificial intelligence, have enabled the study of atherosclerosis and IH with unprecedented single-cell and spatial precision. Numerous studies have pinpointed gene hubs regulating pivotal atherogenic and atheroprotective signaling pathways as potential therapeutic candidates. Leveraging advancements in viral and nonviral gene therapy (GT) platforms, gene editing technologies, and cutting-edge biomaterial reservoirs for delivery uniquely positions us to develop safe, efficient, and targeted GTs for PAD-related diseases. Gene therapies appear particularly fitting for ex vivo genetic engineering of IH-resistant vein grafts. This manuscript highlights currently available state-of-the-art multiomics approaches, explores promising GT-based candidates, and details GT delivery modalities employed by our laboratory and others to thwart mid-term vein graft failure caused by IH, as well as other PAD-related conditions. The potential clinical translation of these targeted GTs holds the promise to revolutionize PAD treatment, thereby enhancing patients' quality of life and life expectancy.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Brennan PG, Mota L, Aridi T, et al. Advancements in Omics and Breakthrough Gene Therapies: A Glimpse into the Future of Peripheral Artery Disease. Ann Vasc Surg. 2024. PMID: 38582204. doi:10.1016/j.avsg.2024.01.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。